| 货号 | 17375-5mg |
| 描述 | Inhibiting renal glucose reabsorption through the sodium-glucose cotransporter (SGLT) offers an insulin-independent alternative to controlling blood glucose concentrations in patients with type 2 diabetes.1,2 The majority of glucose is reabsorbed from glomerular filtrate by SGLT2, which is predominantly expressed in the kidney S1 segment of the proximal tubule. Empagliflozin is a potent SGLT2 inhibitor (IC50 = 3.1 nM) that demonstrates a high degree of selectivity (>2,500-fold) over SGLT1, 4, 5, and 6.3 In clinical trials of patients with type 2 diabetes, empagliflozin was shown to lower fasting and postprandial glucose levels by increasing total glucose excretion, improving β-cell function, and shifting substrate utilization from glucose to lipids.4 |
| 别名 | BI 10773; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Tahrani, A.A. and Barnett, A.H. Dapagliflozin: A sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther. 1(2), 45-56 (2010). 2.Komoroski, B.,Vachharajani, N.,Feng, Y., et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clinical Pharmacology and Therapeutics 85(5), 513-519 (2009). 3.Grempler, R.,Thomas, L.,Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose contransporter-2 (SGLT-2) inhibitor: Characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes. Metab. 14(1), 83-90 (2012). 4.Ndefo, U.A.,Anidiobi, N.O.,Basheer, E., et al. Empagliflozin (Jardiance): A novel SGLT2 inhibitor for the treatment of type-2 diabetes. P.T. 40(6), 364-368 (2015). | |
| 运输条件 | Wet ice in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 450.9 |
| 分子式 | C23H27ClO7 |
| CAS号 | 864070-44-0 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |